<DOC>
	<DOC>NCT00638534</DOC>
	<brief_summary>The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5 days in children with acute otitis media (AOM). Secondary objectives are to assess Efficacy, Pharmacokinetics and Acceptability of telithromycin 20 mg/kg qd for 5 days in children with AOM.</brief_summary>
	<brief_title>Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Subjects who are weighing 40 kg or less. If female, premenarchal status is required. Subjects with signs of infection according to middle ear signs and general signs or symptoms such as otalgia, fever, sleep disturbance, irritability, inconsolability. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Acute Otitis Media</keyword>
	<keyword>AOM</keyword>
	<keyword>children</keyword>
	<keyword>Child</keyword>
</DOC>